Abstract
The efficient and short synthetic route to the structurally novel bimodal ligand NETA for antibody-targeted radiation therapy (radioimmunotherapy, RIT) of cancer was developed. The structure of NETA was determined by X-ray crystallography. The arsenazo-based UV spectroscopic complexation kinetics data suggest that NETA is a promising chelator for use in RIT applications of (212)Bi, (213)Bi, and (177)Lu.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Acetates / chemical synthesis*
-
Acetates / chemistry
-
Acetates / pharmacology*
-
Bismuth
-
Chelating Agents / chemical synthesis*
-
Chelating Agents / chemistry
-
Chelating Agents / pharmacology
-
Crystallography, X-Ray
-
Drug Design
-
Heterocyclic Compounds / chemical synthesis*
-
Heterocyclic Compounds / chemistry
-
Heterocyclic Compounds / pharmacology*
-
Kinetics
-
Ligands
-
Lutetium
-
Molecular Conformation
-
Molecular Structure
-
Radioimmunotherapy
-
Radioisotopes*
Substances
-
(2-(4,7-biscarboxymethyl(1,4,7)triazacyclonona-1-yl-ethyl)carbonylmethylamino)acetic acid
-
(2-(4,7-biscarboxymethyl(1,4,7)triazacyclononan-1-ylethyl)carbonylmethylamino)acetic acid
-
Acetates
-
Chelating Agents
-
Heterocyclic Compounds
-
Ligands
-
Radioisotopes
-
Lutetium
-
Bismuth